Assessing therapeutic efficacy of MEK inhibition in a KrasG12C-driven mouse model of lung cancer
Articolo
Data di Pubblicazione:
2018
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Male; Mice; Middle Aged; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Tumor Suppressor Protein p53
Elenco autori:
Li S.; Liu S.; Deng J.; Akbay E.A.; Hai J.; Ambrogio C.; Zhang L.; Zhou F.; Jenkins R.W.; Adeegbe D.O.; Gao P.; Wang X.; Paweletz C.P.; Herter-Sprie G.S.; Chen T.; Gutierrez-Quiceno L.; Zhang Y.; Merlino A.A.; Quinn M.M.; Zeng Y.; Yu X.; Liu Y.; Fan L.; Aguirre A.J.; Barbie D.A.; Yi X.; Wong K.-K.
Link alla scheda completa:
Pubblicato in: